About Visiox Pharma
Visiox Pharma is a Healthcare company based in Tarrytown (United States) founded in 2021 by Zachry Rome. Therapeutics for ophthalmic diseases including glaucoma are developed. Visiox Pharma has raised $7 million across 1 funding round from investors including Founding Partners. Its chief executive, as recorded, is Ryan Bleeks. Its focus areas include Life Sciences, Ophthalmology, Drugs and Glaucoma. Its legal entity is VISIOX PHARMACEUTICALS, INC. Its competitors include Qlaris Bio, TearClear and Aria Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Visiox Pharma was founded in 2021 and is based in Tarrytown, United States. Focus is placed on the development of therapeutics targeting ophthalmic conditions. Drug candidates such as PDP-716, a brimonidine formulation for ocular hypertension and open-angle glaucoma, and SDN-037, a topical difluprednate used for post-surgical inflammation and pain, are advanced by the company in the pharmaceutical sector. Operations center on innovative treatments for eye-related disorders.
- Headquarters Tarrytown, United States
- Founders Zachry Rome
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website visioxpharma.com
- Legal Name Visiox Pharmaceuticals, Inc.
- Total Equity Funding$7M (USD)
in 1 rounds
- Latest Funding Round$7M (USD), Seed
Aug 2022
- Investors
Funding Insights of Visiox Pharma
Visiox Pharma has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Seed round of $7 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 1
- Last Round Seed — $7M
- First Round $7M
(Aug 2022)
- Investors Count 1
All 1 funding rounds of Visiox Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $7M | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Visiox Pharma
Visiox Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Founding Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Delivers expert business consulting services to support organizational growth and strategy. | 2018 | thefoundingpartners.com | London, United Kingdom |
Investor details for Visiox Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Visiox Pharma
2 people are tracked at Visiox Pharma (2 in leadership).
| Name | Role | Group |
|---|---|---|
Zachry Rome | Co-Founder | Leadership |
Ryan Bleeks | CEO | Leadership |
Complete people profiles for Visiox Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Visiox Pharma
2 dated milestones of Visiox Pharma across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Visiox Pharma is founded.
- Funding First funding round of $7.0M.
Competitors of Visiox Pharma
Visiox Pharma has 3 listed competitors in our database, 3 of them funded. They include Qlaris Bio, TearClear and Aria Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qlaris.bio | 2019 | United States | $49.03M | AI-based technology is developed for treating ophthalmic diseases. | ||
| tearclear.com | 2015 | Copley Township, United States | $31.98M | Filter technology for preservative-free ophthalmic drugs is developed. | ||
| ariapharmaceuticals.com | 2015 | Palo Alto, United States | $14.31M | Develops innovative drug technologies for multiple diseases. |
Detailed competitors of Visiox Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Visiox Pharma (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Visiox Pharma
Complete news archive for Visiox Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Visiox Pharma
Visiox Pharma was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Visiox Pharma is headquartered in Tarrytown, United States. It is registered at Tarrytown, New York, United States.
Ryan Bleeks is the CEO of Visiox Pharma, as recorded in our data.
Visiox Pharma is a funded company, having raised a total of $7M across 1 funding round to date. The company's 1st funding round was a Seed of $7M, raised on Aug 2022.
Visiox Pharma was founded in 2021 and is based in Tarrytown, United States. Focus is placed on the development of therapeutics targeting ophthalmic conditions. Drug candidates such as PDP-716, a brimonidine formulation for ocular hypertension and open-angle glaucoma, and SDN-037, a topical difluprednate used for post-surgical inflammation and pain, are advanced by the company in the pharmaceutical sector. Operations center on innovative treatments for eye-related disorders.
Visiox Pharma's top competitors include Qlaris Bio, TearClear and Aria Pharmaceuticals.
Visiox Pharma has 1 investor. Key investors include Founding Partners.
Visiox Pharma operates through Visiox Pharmaceuticals, Inc..